The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...

A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient ...

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

The American Academy of Ophthalmology (AAO) annual meeting and expo are fast approaching on October 18 and will run through October 20 at the Orange County Convention Center West in Orlando. In a ...

This phase 2b study (ASPIRE) is currently underway. UNITY believes that its lead candidate, UBX1325 (foselutoclax), with its unique mechanism of action, has the potential to improve long-term visual ...

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.

The results of a new retrospective cohort study suggest that use of curcuma-based nutritional supplements (CBNS) may be associated with the reduced risk of developing age-related macular degeneration ...

Christine N. Kay, MD, discussed her presentation, "Deuterated vitamin A preserves vision in Stargardt’s disease (TEASE study)" which was given at this year's American Academy of Ophthalmology meeting ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52. The 2-year Phase 2b RESTORE trial has achieved its primary and key secondary endpoints ...

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection. The ideal syringe for administering intravitreal injections does not exist ...